ES2739814T3 - Compuestos de (3-(5-cloro-2-hidroxifenil)-1-benzoil-1H-pirazol sustituidos como inhibidores de histona desmetilasa - Google Patents
Compuestos de (3-(5-cloro-2-hidroxifenil)-1-benzoil-1H-pirazol sustituidos como inhibidores de histona desmetilasa Download PDFInfo
- Publication number
- ES2739814T3 ES2739814T3 ES14813387T ES14813387T ES2739814T3 ES 2739814 T3 ES2739814 T3 ES 2739814T3 ES 14813387 T ES14813387 T ES 14813387T ES 14813387 T ES14813387 T ES 14813387T ES 2739814 T3 ES2739814 T3 ES 2739814T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- compounds
- mmol
- cancer
- mao
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*(*)S(C1=C(*)C(C(O)=O)=C(*)*C1*)(=O)=O Chemical compound C*(*)S(C1=C(*)C(C(O)=O)=C(*)*C1*)(=O)=O 0.000 description 6
- TZKDPBATMOYEBO-UHFFFAOYSA-N CN(C)S(c1cccc(C(OC)=O)c1)(=O)=O Chemical compound CN(C)S(c1cccc(C(OC)=O)c1)(=O)=O TZKDPBATMOYEBO-UHFFFAOYSA-N 0.000 description 1
- QPQVGKOKFZZZMQ-UHFFFAOYSA-N CS(c1cc(C(NN)=O)ccc1)(=O)=O Chemical compound CS(c1cc(C(NN)=O)ccc1)(=O)=O QPQVGKOKFZZZMQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
- C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/921,895 US9266838B2 (en) | 2011-08-15 | 2013-06-19 | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
| PCT/US2014/043179 WO2014205213A1 (en) | 2013-06-19 | 2014-06-19 | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2739814T3 true ES2739814T3 (es) | 2020-02-04 |
Family
ID=52105283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14813387T Active ES2739814T3 (es) | 2013-06-19 | 2014-06-19 | Compuestos de (3-(5-cloro-2-hidroxifenil)-1-benzoil-1H-pirazol sustituidos como inhibidores de histona desmetilasa |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3010915B1 (https=) |
| JP (1) | JP6525162B2 (https=) |
| KR (1) | KR102288648B1 (https=) |
| CN (2) | CN105555784B (https=) |
| AU (1) | AU2014281398B2 (https=) |
| BR (1) | BR112015032113B1 (https=) |
| CA (1) | CA2915817C (https=) |
| ES (1) | ES2739814T3 (https=) |
| IL (1) | IL243200B (https=) |
| MX (1) | MX366949B (https=) |
| NZ (1) | NZ715331A (https=) |
| SG (2) | SG10201710543PA (https=) |
| WO (1) | WO2014205213A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ715331A (en) * | 2013-06-19 | 2019-09-27 | The Univ Of Utah Research Foundation | Substituted (e)-n’-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
| MX373103B (es) | 2014-02-13 | 2020-04-17 | Incyte Holdings Corp | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016119031A1 (pt) * | 2015-01-29 | 2016-08-04 | Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig | Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| CA2987876A1 (en) | 2015-06-12 | 2016-12-15 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| AU2016382512A1 (en) | 2015-12-30 | 2018-07-12 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| WO2017158136A1 (en) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| JP6999574B2 (ja) | 2016-04-22 | 2022-01-18 | インサイト・コーポレイション | Ｌｓｄ１阻害剤の製剤 |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| WO2018083138A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| CN108727377A (zh) * | 2017-04-14 | 2018-11-02 | 四川大学 | 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途 |
| MX2020001323A (es) | 2017-08-03 | 2020-03-20 | Oryzon Genomics Sa | Metodos para tratar alteraciones del comportamiento. |
| WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
| CN108689960B (zh) * | 2018-06-07 | 2022-03-04 | 济南大学 | 5-苯亚甲基-2-苯基噻唑酮类化合物及其制备和应用 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| SG11202109159VA (en) | 2019-03-20 | 2021-10-28 | Oryzon Genomics Sa | Methods of treating borderline personality disorder |
| ES3053813T3 (en) | 2019-03-20 | 2026-01-26 | Oryzon Genomics Sa | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| CN114341366A (zh) | 2019-07-05 | 2022-04-12 | 奥莱松基因组股份有限公司 | 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法 |
| CN111471096B (zh) * | 2020-01-15 | 2022-02-18 | 上海众启生物科技有限公司 | 用于阿尔茨海默症自身抗体检测的含有adarb1蛋白片段组合物 |
| EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
| JP2024513260A (ja) | 2021-04-08 | 2024-03-22 | オリゾン ジェノミックス ソシエダッド アノニマ | 骨髄癌処置のためのｌｓｄ１阻害剤の組み合わせ |
| CN119546292A (zh) | 2022-05-09 | 2025-02-28 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法 |
| JP2025516648A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法 |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| CN116444437B (zh) * | 2023-03-08 | 2025-09-16 | 曲靖师范学院 | 抗癌医药达洛鲁胺的合成方法 |
| CN116813569B (zh) * | 2023-07-10 | 2024-07-02 | 衡阳市中心医院 | 一种抗癌药中间体的制备方法和抗癌药的制备方法 |
| WO2025188857A1 (en) * | 2024-03-05 | 2025-09-12 | University Of Florida Research Foundation, Incorporated | Hdac8 degraders and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005324024B2 (en) * | 2005-01-07 | 2011-02-17 | F. Hoffmann-La Roche Ag | [4-(Heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| WO2006136008A1 (en) * | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
| WO2007008143A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
| EP2376435A2 (en) * | 2009-01-14 | 2011-10-19 | Dow AgroSciences LLC | Synergistic fungicidal compositions including hydrazone derivatives and copper |
| US9051296B2 (en) * | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| CA2727890A1 (en) * | 2010-01-13 | 2011-07-13 | Norbert Kartner | Compounds, compositions and treatments for v-atpase related diseases |
| AU2011328237A1 (en) * | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
| JP6122006B2 (ja) * | 2011-08-15 | 2017-04-26 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | ヒストン脱メチル化酵素阻害剤としての、置換された（ｅ）−ｎ’−（１−フェニルエチリデン）ベンゾヒドラジド類似体 |
| NZ715331A (en) * | 2013-06-19 | 2019-09-27 | The Univ Of Utah Research Foundation | Substituted (e)-n’-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
-
2014
- 2014-06-19 NZ NZ71533114A patent/NZ715331A/en not_active IP Right Cessation
- 2014-06-19 MX MX2015018032A patent/MX366949B/es active IP Right Grant
- 2014-06-19 SG SG10201710543PA patent/SG10201710543PA/en unknown
- 2014-06-19 EP EP14813387.9A patent/EP3010915B1/en not_active Not-in-force
- 2014-06-19 CA CA2915817A patent/CA2915817C/en active Active
- 2014-06-19 ES ES14813387T patent/ES2739814T3/es active Active
- 2014-06-19 SG SG11201510376QA patent/SG11201510376QA/en unknown
- 2014-06-19 AU AU2014281398A patent/AU2014281398B2/en not_active Ceased
- 2014-06-19 WO PCT/US2014/043179 patent/WO2014205213A1/en not_active Ceased
- 2014-06-19 KR KR1020167001538A patent/KR102288648B1/ko not_active Expired - Fee Related
- 2014-06-19 JP JP2016521574A patent/JP6525162B2/ja not_active Expired - Fee Related
- 2014-06-19 CN CN201480045891.0A patent/CN105555784B/zh not_active Expired - Fee Related
- 2014-06-19 CN CN201910116764.XA patent/CN110015984A/zh active Pending
- 2014-06-19 BR BR112015032113-5A patent/BR112015032113B1/pt not_active IP Right Cessation
-
2015
- 2015-12-17 IL IL243200A patent/IL243200B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014281398A1 (en) | 2016-01-21 |
| BR112015032113B1 (pt) | 2019-01-29 |
| MX2015018032A (es) | 2016-10-03 |
| EP3010915B1 (en) | 2019-05-08 |
| CA2915817C (en) | 2022-12-13 |
| JP6525162B2 (ja) | 2019-06-05 |
| IL243200B (en) | 2020-10-29 |
| KR20160024929A (ko) | 2016-03-07 |
| KR102288648B1 (ko) | 2021-08-12 |
| MX366949B (es) | 2019-07-30 |
| BR112015032113A2 (pt) | 2017-03-21 |
| SG10201710543PA (en) | 2018-02-27 |
| CA2915817A1 (en) | 2014-12-24 |
| AU2014281398B2 (en) | 2018-10-04 |
| EP3010915A4 (en) | 2016-12-28 |
| JP2016523256A (ja) | 2016-08-08 |
| CN105555784B (zh) | 2019-03-15 |
| CN105555784A (zh) | 2016-05-04 |
| SG11201510376QA (en) | 2016-01-28 |
| EP3010915A1 (en) | 2016-04-27 |
| IL243200A0 (en) | 2016-02-29 |
| CN110015984A (zh) | 2019-07-16 |
| NZ715331A (en) | 2019-09-27 |
| WO2014205213A1 (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2739814T3 (es) | Compuestos de (3-(5-cloro-2-hidroxifenil)-1-benzoil-1H-pirazol sustituidos como inhibidores de histona desmetilasa | |
| ES2821548T3 (es) | Análogos de (E)-N'-(1-feniletiliden) benzohidrazida sustituida como inhibidores de desmetilasas de histonas | |
| WO2017004519A1 (en) | Substituted benzohydrazide analogs as histone demethylase inhibitors | |
| US20180092866A1 (en) | Substituted n-([1,1'-biphenyl]-3-yl)-[1,1'-biphenyl]-3-carboxamide analogs as inhibitors for beta-catenin/b-cell lymphoma 9 interactions | |
| US9642857B2 (en) | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors | |
| US11542254B2 (en) | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors | |
| US20250346582A1 (en) | Spleen tyrosine kinase inhibitors and methods of use thereof | |
| NZ621078B2 (en) | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |